AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14499772
Drug: Lansoprazole, clarithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, clarithromycin, and amoxicillin (LCA)
Trial: 10655965
Drug: EPA/DHA (1.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA (1.05 g EPA plus 0.55 g DHA)
Trial: 10655965
Drug: Alpha-linolenic acid
RxNorm normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-linolenic acid (6.8 g/d)
Trial: 2065506
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid injection (1 or 2 knees)
Trial: 6132218
Drug: Low-residue liquid
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-residue liquid supplement
Trial: 12784123
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg THC
Trial: 12784123
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg THC
Trial: 24164904
Drug: Rabeprazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Trial: 22389273
Drug: No supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplementation with oral nutrients (standard diet)
Trial: 18398307
Drug: Purified Chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Chick Embryo Cell Vaccine (PCECV) administered as a three-dose regimen (1.0 mL or 0.5 mL)
Trial: 18398307
Drug: Purified Verocell
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Verocell Rabies Vaccine (PVRV) administered as a three-dose regimen (0.5 mL)
Trial: 10912985
Drug: Control (acid‐mantle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (acid‐mantle cream)
Trial: 9072226
Drug: No administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration of T3
Trial: 1984366
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine with 1:200,000 epinephrine through the single catheter
Trial: 1984366
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.5% bupivacaine with or without 1:200,000 epinephrine through each of the two catheters
Trial: 6407054
Drug: Clobazam 20
RxNorm normalized name: cloBAZam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam 20 mg (an anxiolytic 1,5‐benzodiazepine derivative)
Trial: 26095194
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml 0.25% bupivacaine (Group B)
Trial: 26095194
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml saline (Group S)
Trial: 23536104
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose drink
Trial: 16701989
Drug: Once-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily budesonide/formoterol (80/4.5 microg, 2 inhalations in the evening)
Trial: 16701989
Drug: Twice-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily budesonide/formoterol (80/4.5 microg, 1 inhalation)
Trial: 16701989
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 microg, 1 inhalation in the evening)
Trial: 16701989
Drug: Budesonide/formoterol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol therapy
Trial: 15243815
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (specifics not provided)
Trial: 15243815
Drug: C(6) antibody
RxNorm normalized name: FD & C Yellow #6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C(6) antibody testing
Trial: 11345361
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogen daily for three months
Trial: 3044484
Drug: Cephradine prophylaxis
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephradine prophylaxis (3 peri-operative doses)
Trial: 23067311
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GSK1144814
Trial: 19840020
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDChT) with autologous stem cell support (ASCS)
Trial: 19840020
Drug: Sequential HD
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential HD regimen with one or two conventional chemotherapy cycles followed by two or three HD cycles of CE
Trial: 19840020
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDChT)
Trial: 11871864
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy
Trial: 16998274
Drug: Fasudil hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil hydrochloride (30 mg by intravenous injection over 30 minutes three times a day for 14 days)
Trial: 16998274
Drug: Nimodipine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (1 mg/hr by continuous intravenous infusion for 14 days)
Trial: 9494056
Drug: Lifestyle program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle program including a low-fat diet and weekly moderate exercise (Experimental group, N = 27)
Trial: 3668249
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-selective agent) with or without diuretics and/or vasodilators
Trial: 24015934
Drug: NEURO (low-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEURO (low-frequency repetitive transcranial magnetic stimulation plus occupational therapy)
Trial: 24015934
Drug: constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: constraint-induced movement therapy
Trial: 12814142
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (AB) 1 mg/kg/day (weight < 75 kg = 50 mg/day; weight ≥ 75 kg = 100 mg/day)
Trial: 22479740
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 100 mg once daily for 72 hrs
Trial: 22479740
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 100 mg i.v. 6 hourly for 72 hrs
Trial: 23283393
Drug: Thrice BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice BCG vaccinations (0.1 mL intradermal injection, 3 times every 4 weeks)
Trial: 23283393
Drug: Single BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single BCG vaccination (0.1 mL intradermal injection)
Trial: 17190103
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution with Na/K molar ratio of 1
Trial: 17190103
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution with Na/K molar ratio of 2
Trial: 17190103
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution with Na/K molar ratio of 3
Trial: 17190103
Drug: Test solution
RxNorm normalized name: Candin Skin Test Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solution with Na/K molar ratio of 4
Trial: 8575136
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) at 3-5 mg/kg/day
Trial: 8575136
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Methotrexate (MTX) at 2.5 mg every 12 hours for 3 consecutive doses each week up to 15 mg/week
Trial: 2791446
Drug: 3200 mg
RxNorm normalized name: sodium chloride 3200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3200 mg ibuprofen
Trial: 31273459
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (all three diagnoses)
Trial: 26001510
Drug: High-rate therapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-rate therapy
Trial: 26001510
Drug: Long-delay therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-delay therapy
Trial: 24113668
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (b-INS)
Trial: 21586650
Drug: CoQ10 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (100 mg)
Trial: 16926172
Drug: new formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new formulation (vitamins B1, B2, B6, B12, and folic acid)
Trial: 16926172
Drug: old formulation
RxNorm normalized name: Poly Hist PD (old formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: old formulation (vitamins B1, B2, B6, and B12)
Trial: 11390122
Drug: Aerodiol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerodiol 300 microg daily
Trial: 11390122
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol (50 microg/day, 2 patches per week)
Trial: 8313635
Drug: 1% griseofulvin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% griseofulvin spray applied twice daily for 14 days
Trial: 8313635
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) applied twice daily for 14 days
Trial: 8313635
Drug: 1% griseofulvin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% griseofulvin spray applied once daily for 4 weeks
Trial: 8313635
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) applied once daily for 4 weeks
Trial: 28810251
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg q.d. for 1 month followed by 5 mg q.d. for maintenance
Trial: 28810251
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg b.i.d. for 1 month followed by 45 mg b.i.d. for maintenance
Trial: 28810251
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg q.d. for 1 month followed by standard dose without reduction
Trial: 25412795
Drug: ALV 600
RxNorm normalized name: ALV-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALV 600 mg QD + PR
Trial: 25412795
Drug: ALV 800
RxNorm normalized name: ALV-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALV 800 mg QD + PR
Trial: 25412795
Drug: ALV 400
RxNorm normalized name: ALV-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALV 400 mg BID + PR
Trial: 22324720
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% tacrolimus ointment
Trial: 25262434
Drug: Rosuvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (5 mg/day)
Trial: 16248952
Drug: Tumor vaccine
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor vaccine
Trial: 16795983
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (adjuvant treatment only)
Trial: 16795983
Drug: DTH response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DTH response positive patients (from tumor vaccine group)
Trial: 14515287
Drug: Postoperative portal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative portal vein infusion (PVI) of 5‐fluorouracil (5‐FU) (1 g 5‐FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24‐h period for 7 days)
Trial: 14515287
Drug: Rectal cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal cancer
Trial: 11113418
Drug: Mechanical force
RxNorm normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical force of injection at 90 minutes
Trial: 11113418
Drug: Overall intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall intervention (hand injection)
Trial: 11113418
Drug: Hand injections
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand injections
Trial: 6229319
Drug: gallamine (0.29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallamine (0.29 mg X kg‐1)
Trial: 6229319
Drug: d‐tubocurarine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine (0.04 mg X kg‐1)
Trial: 6229319
Drug: metocurine (0.014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metocurine (0.014 mg X kg‐1)
Trial: 6229319
Drug: pancuronium (0.007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium (0.007 mg X kg‐1)
Trial: 26915605
Drug: Nefiracetam 900
RxNorm normalized name: Nefiracetam
DrugBank: Nefiracetam (DB13082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefiracetam 900 mg/day for 12 weeks
Trial: 20946966
Drug: Clofarabine (Clo)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (Clo) + Fludarabine (Flu) 10:30 mg/m²
Trial: 20946966
Drug: Clofarabine (Clo)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (Clo) 40 mg/m²
Trial: 20946966
Drug: Clofarabine (Clo)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (Clo) 20:20 mg/m²
Trial: 20946966
Drug: Clofarabine (Clo)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (Clo) 30:10 mg/m²
Trial: 20946966
Drug: Single-agent Clo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent Clo 40 mg/m²
Trial: 19273465
Drug: 15-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with usual care support
Trial: 19273465
Drug: 15-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with weekly support
Trial: 9292621
Drug: Linopirdine (LPD)
RxNorm normalized name: linopirdine
DrugBank: Linopirdine (DB13806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linopirdine (LPD) 40 mg TID for 4 weeks
Trial: 8328789
Drug: Spiramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin (1 g, orally, twice daily for 14 days)
Trial: 8328789
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg, orally, twice daily for 14 days)
Trial: 185885
Drug: Basal medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal medium (no lipolytic agents)
Trial: 30132785
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 40,000 units subcutaneously weekly up to three doses or until ICU discharge
Trial: 26078323
Drug: Killed whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole‐cell oral cholera vaccine (OCV)
Trial: 23919622
Drug: ART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART plus FutureLife porridge nutritional supplement (NS) (388 kcal/day)
Trial: 15058405
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene care regimen
Trial: 11273790
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after oxygen (FiO(2)1.0)
Trial: 11273790
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after hypoxic gas mixture (FiO(2)0.15)
Trial: 26933398
Drug: HMB +
RxNorm normalized name: Hydroxymethylbutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB + Whey protein (3 g/day HMB and 36.6 g/day whey protein)
Trial: 26933398
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (36.6 g/day)
Trial: 25633712
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of 0.2% resiquimod gel (arm B)
Trial: 25633712
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (arm A)
Trial: 25633712
Drug: NY‐ESO‐1 protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NY‐ESO‐1 protein plus Montanide with or without topical resiquimod
Trial: 23074313
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Trial: 23074313
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus dosing of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Trial: 23074313
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus dosing of beta-lactam antibiotics
Trial: 18333937
Drug: Oxytocin +
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin + ergometrine maleate 0.25 mg + oxytocin 20 iu
Trial: 9257790
Drug: Inhaled lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lysine acetylsalicylate (LASA) 720 mg in 4 ml saline solution
Trial: 30354558
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg subcutaneously daily)
Trial: 12800859
Drug: Flavoured water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavoured water (0.1 g carbohydrate, Na+ 6 mmol x l(‐1))
Trial: 12800859
Drug: Placebo (Na+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Na+ 2 mmol x l(‐1))
Trial: 12800859
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (6.5% carbohydrate, 6.5 g carbohydrate, Na+ 21 mmol x l(‐1))
Trial: 18328410
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution
Trial: 6435484
Drug: TTS-nitroglycerin (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS-nitroglycerin (transdermal therapeutic system)
Trial: 6435484
Drug: 2% nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nitroglycerin ointment (0.5 inch applied at 8 hr intervals over 10 cm2 of skin)
Trial: 24701539
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied in a single sitting divided into four sessions.
Trial: 24701539
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control group (similar treatment without activating the LASER unit).
Trial: 10629930
Drug: Amiridin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiridin (80 mg daily for 10 weeks)
Trial: 10629930
Drug: Cerebrolysin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (20 intravenous infusions of 30 ml in 150 ml of physiologic solution during 4 weeks) followed by amiridin (80 mg daily for 10 weeks)
Trial: 6101934
Drug: Beta-adrenoreceptor antagonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoreceptor antagonists (propranolol, oxprenolol, practolol, metoprolol, tolamolol)
Trial: 28976976
Drug: 20-week prednisolone
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-week prednisolone treatment
Trial: 28976976
Drug: 32-week prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32-week prednisolone treatment